Jane Street Group LLC Makes New Investment in Abeona Therapeutics Inc (NASDAQ:ABEO)

Jane Street Group LLC purchased a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,216 shares of the biopharmaceutical company’s stock, valued at approximately $84,000.

A number of other hedge funds also recently made changes to their positions in ABEO. Renaissance Technologies LLC lifted its stake in shares of Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after buying an additional 429,456 shares in the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter worth about $1,732,000. abrdn plc lifted its position in Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after acquiring an additional 200,647 shares in the last quarter. Western Standard LLC boosted its stake in Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares during the last quarter. Finally, Rosalind Advisors Inc. increased its holdings in Abeona Therapeutics by 4.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after purchasing an additional 82,000 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ABEO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th. Finally, StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 9th.

Abeona Therapeutics Stock Down 9.3 %

Abeona Therapeutics stock opened at $5.09 on Wednesday. The firm has a 50 day simple moving average of $5.95 and a 200 day simple moving average of $5.68. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics Inc has a 1-year low of $3.05 and a 1-year high of $9.01. The firm has a market capitalization of $221.27 million, a price-to-earnings ratio of -1.89 and a beta of 1.46.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.